浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Construction of clinical comprehensive evaluation index system of anti-lung cancer drugs and empirical study
- ZHONGGUO YAOFANG Vol. 34, Issue 11, Pages: 1313-1319(2023)
- 作者机构：
1.南方医科大学第三附属医院药物临床试验机构办公室，广州 510630
2.中山大学药学院医药经济研究所，广州 510006
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.11.06
CLC： R979.1Published：15 June 2023，
Received：07 November 2022，
Revised：23 May 2023，
扫 描 看 全 文
林思思,陈丽萍,江绮云等.抗肺癌药品临床综合评价指标体系的构建及实证研究[J].中国药房,2023,34(11):1313-1319.
LIN Sisi,CHEN Liping,JIANG Qiyun,et al.Construction of clinical comprehensive evaluation index system of anti-lung cancer drugs and empirical study[J].ZHONGGUO YAOFANG,2023,34(11):1313-1319.
林思思,陈丽萍,江绮云等.抗肺癌药品临床综合评价指标体系的构建及实证研究[J].中国药房,2023,34(11):1313-1319. DOI： 10.6039/j.issn.1001-0408.2023.11.06.
LIN Sisi,CHEN Liping,JIANG Qiyun,et al.Construction of clinical comprehensive evaluation index system of anti-lung cancer drugs and empirical study[J].ZHONGGUO YAOFANG,2023,34(11):1313-1319. DOI： 10.6039/j.issn.1001-0408.2023.11.06.
摘要
目的
2
构建抗肺癌药品临床综合评价指标体系，为药品遴选和临床合理用药提供依据。
方法
2
遵循《药品临床综合评价管理指南（2021年版试行）》相关规定，通过文献分析法初步拟定评价指标体系框架及指标预选池，基于德尔菲法对评价指标进行筛选和修改，运用专家直接打分法及相关计算得到各个指标的权重，从而制定抗肺癌药品临床综合评价指标体系；参考《中国医疗机构药品评价与遴选快速指南》制定抗肺癌药品临床综合评价指标评分细则。使用所建临床综合评价指标体系和评分细则对抗肺癌药品帕博利珠单抗开展实证评价。
结果
2
所构建的抗肺癌药品临床综合评价指标体系包括6个一级指标、15个二级指标，其中一级指标的权重分别为安全性18、有效性38、经济性15、创新性9、适宜性10、可及性10。初步构建了抗肺癌药品临床综合评价指标评分细则。实证评价结果显示，帕博利珠单抗联合化疗方案的综合评分（61分）高于单纯化疗方案（56分），前者的有效性、创新性、适宜性均优于后者，而后者的安全性、经济性均优于前者。
结论
2
所构建的抗肺癌药品临床综合评价指标体系具有可推广落地性，可为临床合理用药提供参考依据。
Abstract
OBJECTIVE
2
To construct a comprehensive evaluation index system for anti-lung cancer drugs， and to provide a basis for drug selection and rational clinical use.
METHODS
2
Based on the
Guidelines for the Management of Comprehensive Clinical Evaluation of Drugs
（2021 edition for trial use）， a preliminary evaluation index system framework and an index preselection pool were initially formulated through literature analysis. The evaluation indices were then selected and modified by using the Delphi method. The weights of each index were determined through expert scoring and relevant calculations， thereby establishing a comprehensive evaluation index system for anti-lung cancer drugs. Referred to
Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions
， scoring detailed rules for clinical comprehensive evaluation indexes of anti-lung cancer drugs were formulated. The constructed comprehensive evaluation index system and scoring detailed rules were applied to conduct empirical evaluation of the anti-lung cancer drug pembrolizumab.
RESULTS
2
The constructed comprehensive evaluation index system for anti-lung cancer drugs included 6 primary indicators and 15 secondary indicators. The weights of the primary indicators were as follows： safety （18）， efficacy （38）， economy （15）， innovation （9）， suitability （10）， and accessibility （10）. The scoring detailed rules for the comprehensive evaluation index system for anti-lung cancer drugs had been preliminarily established. The results of empirical evaluation showed that the comprehensive evaluation score （61 points） of pembrolizumab combined with chemotherapy regimen was higher than that of the monotherapy chemotherapy regimen （56 points）. The former demonstrated superior efficacy， innovation and suitability compared to the latter， while the latter exhibited better safety and economy.
CONCLUSIONS
2
The constructed comprehensive evaluation index system for anti-lung cancer drugs has the potential for generalizability and practical application， providing a reference basis for rational clinical drug use.
关键词
药品临床综合评价肺癌抗肿瘤药物指标体系指标评分细则
Keywords
lung cancerantineoplastic drugsindex systemindicator scoring detailed rules
references
国家卫生健康委办公厅. 国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知[J]. 中华人民共和国国家卫生健康委员会公报，2021（7）：21-28.
国家卫生健康委. 药品临床综合评价管理指南：2021年版试行[S/OL]. （2021-07-28）[2022-10-20]. http：//www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415d84adf-3797b0f4869.shtmlhttp://www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415d84adf-3797b0f4869.shtml.
SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.
郭丽娟. 非小细胞肺癌规范化诊疗及现况分析[D]. 海口：海南医学院，2018.
GETTINGER S，HORN L，JACKMAN D，et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer：results from the CA209-003 study[J]. J Clin Oncol，2018，36（17）：1675-1684.
HERBST R S，ONN A，SANDLER A. Angiogenesis and lung cancer：prognostic and therapeutic implications[J]. J Clin Oncol，2005，23（14）：3243-3256.
肖熠. 贵州省基本医疗保险药品价值评价体系构建及应用研究[D]. 贵阳：贵州医科大学，2021.
国家药品监督管理局. 关于印发化学药品和生物制品说明书规范细则的通知[EB/OL].（2006-05-10）[2022-10-20]. https：//www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20060510010101566.htmlhttps://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20060510010101566.html.
ICER. 2020-2023 ICER value assessment framework[EB/OL]. （2020-01-31）[2022-10-20]. https：//icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdfhttps://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf.
CHERNY N I，DAFNI U，BOGAERTS J，et al. ESMO-magnitude of clinical benefit scale version 1.1[J]. Ann Oncol，2017，28（10）：2340-2366.
CHERNY N I，DE VRIES E G E，DAFNI U，et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score[J]. J Clin Oncol，2019，37（4）：336-349.
LAKDAWALLA D N，DOSHI J A，JrGARRISON L P， et al. Defining elements of value in health care：a health economics approach：an ISPOR special task force report[J]. Value Health，2018，21（2）：131-139.
肖熠，伍红艳，李梦楠，等. 德尔菲法在贵州省基本医疗保险药品价值评价指标体系构建中的应用[J]. 中国初级卫生保健，2021，35（6）：17-20，24.
林威，赵振东，杨志广，等. 药品价值评估指标体系的建立[J]. 中国药房，2013，24（1）：7-10.
夏聪. 上市后药品价值评价指标体系的构建及应用研究[D]. 广州：南方医科大学，2018.
刘炳林，薛斐然. 药物临床价值评估的主要考虑因素及问题[J]. 中国新药杂志，2017，26（5）：504-508.
许军，夏聪，向前，等. 基于药品价值的定价机制研究进展[J]. 中国卫生经济，2016，35（10）：54-58.
罗晓，史丽敏，王汝龙. 药物临床价值评价[J]. 药品评价，2010，7（4）：20-24.
孔凡心，马爱霞，李洪超，等. 公共决策视野下药品临床综合价值的界定、测量与评价[J]. 中国药房，2020，31（5）：539-544.
RAJU P K S. WHO/HAI methodology for measuring medicine prices，availability and affordability，and price components[M]//Medicine Price Surveys，Analyses and Comparisons. Amsterdam：Elsevier，2019：209-228.
赵志刚，董占军，刘建平. 中国医疗机构药品评价与遴选快速指南[J]. 医药导报，2020，39（11）：1457-1465.
MENCOBONI M，CEPPI M，BRUZZONE M，et al. Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world：review and meta-analysis[J]. Cancers，2021，13（6）：1388.
GARON E B，AERTS J，KIM J S，et al. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer：a post hoc analysis of KEYNOTE-189[J]. Lung Cancer，2021，155：53-60.
药智网.帕博利珠单抗注射液说明书[EB/OL].（2021-11-17）[2022-10-22]. https：//zy.yaozh.com/instruct/sms2022- 0228/65.pdfhttps://zy.yaozh.com/instruct/sms2022-0228/65.pdf.
药智网.注射用培美曲塞二钠说明书[EB/OL].（2021-11-17）[2022-10-22]. https：//zy.yaozh.com/instruct/sms2022- 0228/85.pdfhttps://zy.yaozh.com/instruct/sms2022-0228/85.pdf.
段建春，李梦侠，刘秀峰，等. 免疫检查点抑制剂特殊人群应用专家共识[J]. 临床肿瘤学杂志，2022，27（5）：442-454.
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2022[M]. 北京：人民卫生出版社，2022：26-28.
PAZ-ARES L，LUFT A，VICENTE D，et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med，2018，379（21）：2040-2051.
药智网.帕博利珠单抗中标价[EB/OL].（2021-10-09）[2022-10-22]. https：//db.yaozh.com/yaopinzhongbiao/bJWabGloamZplWRilJaUnA= =.htmlhttps://db.yaozh.com/yaopinzhongbiao/bJWabGloamZplWRilJaUnA==.html.
药智网.培美曲塞中标价[EB/OL].（2022-04-21）[2022-10-22]. https：//db.yaozh.com/yaopinzhongbiao/bJeZaGhjZWRllWRilJaXnA= =.htmlhttps://db.yaozh.com/yaopinzhongbiao/bJeZaGhjZWRllWRilJaXnA==.html.
药智网.卡铂中标价[EB/OL].（2022-08-16）[2022-10-22]. https：//db.yaozh.com/yaopinzhongbiao/bJWabGpjbGNklWRilJaXlg= =.htmlhttps://db.yaozh.com/yaopinzhongbiao/bJWabGpjbGNklWRilJaXlg==.html.
WAN N，ZHANG T T，HUA S H，et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC[J]. Cancer Med，2020，9（5）：1683-1693.
国家统计局. 中华人民共和国2020年国民经济和社会发展统计公报[EB/OL].（2021-02-28）[2022-10-22]. http：//www.gov.cn/xinwen/2021-02/28/content_5589283.htmhttp://www.gov.cn/xinwen/2021-02/28/content_5589283.htm.
国家统计局. 2021年居民收入和消费支出情况[EB/OL]. （2021-11-17）[2022-10-22]. www.stats.gov.cn/sj/zxfb/202302/t20230203_1901342.htmlwww.stats.gov.cn/sj/zxfb/202302/t20230203_1901342.html.
0
Views
5
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.